Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Authors
Keywords
-
Journal
Cancer Management and Research
Volume Volume 12, Issue -, Pages 7321-7330
Publisher
Informa UK Limited
Online
2020-08-17
DOI
10.2147/cmar.s216605
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2019) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
- (2019) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
- (2019) Scott S. Tykodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.
- (2019) Arnaud Mejean et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- (2018) Toni K. Choueiri et al. EUROPEAN JOURNAL OF CANCER
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- (2018) Arnaud Méjean et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune consequences of anti-angiogenic therapy in renal cell carcinoma
- (2018) Klaudia K. Brodaczewska et al. Wspolczesna Onkologia-Contemporary Oncology
- Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]
- (2018) Toni K. Choueiri et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
- (2018) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
- (2018) Axel Bex et al. JAMA Oncology
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
- (2018) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions
- (2017) Hussein Merza et al. Current Oncology Reports
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
- (2016) Ajjai Alva et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Targeting the tumor vasculature to enhance T cell activity
- (2015) Evripidis Lanitis et al. CURRENT OPINION IN IMMUNOLOGY
- Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma
- (2015) Katherine A Murphy et al. Human Vaccines & Immunotherapeutics
- Pembrolizumab
- (2015) Leila Khoja et al. Journal for ImmunoTherapy of Cancer
- Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics
- (2013) James H. Finke et al. CANCER JOURNAL
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma
- (2013) A. Ari Hakimi et al. JNCI-Journal of the National Cancer Institute
- Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients
- (2013) Sei Naito et al. UROLOGY
- Axitinib for the Management of Metastatic Renal Cell Carcinoma
- (2013) Bernard Escudier et al. Drugs in research & development
- Cigarette Smoking Is Associated With Advanced Renal Cell Carcinoma
- (2011) Matvey Tsivian et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
- (2010) Alfredo Carrato Mena et al. ANTI-CANCER DRUGS
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies
- (2010) Renaud Grépin et al. Journal of Oncology
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started